Shigeki Shimizu

Dr. Shigeki Shimizu

orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2003
Verified
Journal Article
Closed access
TITakashi Ishida
Takashi Ishida
AUAtae Utsunomiya
Atae Utsunomiya
SIShinsuke Iida
Shinsuke Iida
HIHiroshi Inagaki
Hiroshi Inagaki
YTYoshifusa Takatsuka
Yoshifusa Takatsuka
RURyuzo Ueda
Ryuzo Ueda

1 January 2015 in Internal Medicine
Verified
Journal Article
Closed access
NONaoki Omachi
Naoki Omachi
TKTomoya Kawaguchi
Tomoya Kawaguchi
SSShigeki Shimizu
Shigeki Shimizu
TOTomohisa Okuma
Tomohisa Okuma
MKMasanori Kitaichi
Masanori Kitaichi
AMAkihide Matsumura
Akihide Matsumura
This report describes the case of a 23-year-old man with a mediastinal teratoma. Five months before admission, a chest radiograph during a routine health checkup was normal. Four months before admission, the patient developed sudden onset of mild right-sided chest pain. He gradually developed dyspnea and was admitted to our hospital. Computed tomography revealed a giant tumor that was markedly compressing the right atrium. Urgent surgery was performed, and a ruptured, benign mature teratoma was diagnosed. Mature mediastinal teratomas are benign tumors, but they can rupture and have the potential to grow rapidly, potentially leading to life-threatening complications.

10 September 2004 in Virchows Archiv
Verified
Journal Article
Closed access
PDF file
SSShigeki Shimizu
Shigeki Shimizu
TYTakeo Yoshinouchi
Takeo Yoshinouchi
TNTaio Naniwa
Taio Naniwa
MNMikae Nakamura
Mikae Nakamura
SSShigeki Sato
Shigeki Sato
RURyuzo Ueda
Ryuzo Ueda

12 October 2014 in BioMed Research International
Verified
Journal Article
Open access
PDF file
Kenichi SudaKenichi Suda
Kenichi Suda
KSKatsuaki Sato
Katsuaki Sato
SSShigeki Shimizu
Shigeki Shimizu
KTKenji Tomizawa
Kenji Tomizawa
TTToshiki Takemoto
Toshiki Takemoto
TMTetsuya Mitsudomi
Tetsuya Mitsudomi
The International Association for the Study of Lung Cancer, American Thoracic Society, and European Respiratory Society (IASLC/ATS/ERS) proposed a new classification for lung adenocarcinoma (AD) based on predominant histologic subtypes, such as lepidic, papillary, acinar, solid, and micropapillary; this system reportedly reflects well outcomes of patients with surgically resected lung AD. However, the prognostic implication of predominant histologic subtypes in lymph nodes metastases is unclear so far. In this study, we compared predominant subtypes between primary lung tumors and lymph node metastatic lesions in 24 patients with surgically treated lung adenocarcinoma with lymph node metastases. Additionally, we analyzed prognostic implications of these predominant histologic subtypes. We observed several discordance patterns between predominant subtypes in primary lung tumors and lymph node metastases. Concordance rates were 22%, 64%, and 100%, respectively, in papillary-, acinar-, and solid-predominant primary lung tumors. We observed that the predominant subtype in the primary lung tumor (HR 12.7,P = 0.037), but not that in lymph node metastases (HR 0.18,P = 0.13), determines outcomes in patients with surgically resected lung AD with lymph node metastases.

1 December 2016 in Lung Cancer
Verified
Journal Article
Closed access
KTKenji Tomizawa
Kenji Tomizawa
MNMasaya Nishino
Masaya Nishino
YSYuichi Sesumi
Yuichi Sesumi
YKYoshihisa Kobayashi
Yoshihisa Kobayashi
KSKatsuaki Sato
Katsuaki Sato
TMTetsuya Mitsudomi
Tetsuya Mitsudomi

29 May 2023 in Anticancer Research
Verified
Journal Article
Open access
PDF file
KKKensuke Kanaoka
Kensuke Kanaoka
ATAkihiro Tamiya
Akihiro Tamiya
YIYuji Inagaki
Yuji Inagaki
YTYoshihiko Taniguchi
Yoshihiko Taniguchi
KNKeiko Nakao
Keiko Nakao
SSShigeki Shimizu
Shigeki Shimizu
Background/Aim: Disparities in the results of next-generation sequencing-based multiplex gene panel tests and those of single-gene tests when detecting epidermal growth factor receptor (EGFR) mutations in non-small-cell lung cancer (NSCLC) have been reported. However, the possible underlying causes have not been investigated. The aim of this study was to explore the possibilities and causes of false results obtained using cobas® EGFR Mutation Test v2 (cobas® EGFR) and Oncomine Dx Target Test (ODxTT). Patients and Methods: The data of patients with NSCLC who underwent gene assessment using both cobas® EGFR and ODxTT between April 2021 and May 2022 were retrospectively reviewed. Disparate results of EGFR mutation analyses were then reviewed. Results: One hundred and sixteen patients were included in the analysis. The results of six samples were inconsistent. In four samples, exon 20 insertion mutations were detected using cobas® EGFR, but not identified using ODxTT. A fragment analysis was performed on three of the four samples, and all showed negative results for exon 20 insertion. Furthermore, one false negative result was obtained in the ODxTT for both exon 19 deletion and L858R mutations. For exon 19 deletion mutation, a single nucleotide variant from adenine to thymine was identified close to the mutation site. Conclusion: False positives for exon 20 insertion may occur when using cobas® EGFR, and false negatives for exon 19 deletion and L858R mutations may occur when using ODxTT.